Extavia News and Research

RSS
FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

New syndicated report covers the use of DMAs for treatment of MS published

New syndicated report covers the use of DMAs for treatment of MS published

BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

FDA approves Extavia for multiple sclerosis

FDA approves Extavia for multiple sclerosis